46868-19-3
46868-19-3
Chemical Structure
N-Desmethylnefopam
- CAS No.: 46868-19-3
- Formula:C16H17NO
- Molecular Weight:239.31
IUPAC Name: 1-phenyl-3,4,5,6-tetrahydro-1H-benzo[f][1,4]oxazocine
InChIKey: ZMOHJRCONJZNKH-UHFFFAOYSA-N
SMILES: C1(C2=CC=CC=C2)OCCNCC3=CC=CC=C31
Biological Activity: N-Desmethylnefopam is the main metabolite of Nefopam. N-Desmethylnefopam is a centrally-acting but non-opioid analgesic agent, for the relief of moderate to severe pain. Nefopam targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
N-Desmethylnefopam | N-Desmethylnefopam is the main metabolite of Nefopam. N-Desmethylnefopam is a centrally-acting but non-opioid analgesic agent, for the relief of moderate to severe pain. Nefopam targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-Desmethylnefopam-d5 (hydrochloride) | N-Desmethylnefopam-d5 (hydrochloride) is a deuterium labeled N-Desmethylnefopam hydrochloride. N-Desmethylnefopam hydrochloride is the main metabolite of Nefopam. N-Desmethylnefopam hydrochloride is a centrally-acting but non-opioid analgesic agent, for the relief of moderate to severe pain. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-Desmethylnefopam-d5 | N-Desmethylnefopam-d5 is the deuterium labeled N-Desmethylnefopam (HY-133115). N-Desmethylnefopam is the main metabolite of Nefopam. N-Desmethylnefopam is a centrally-acting but non-opioid analgesic agent, for the relief of moderate to severe pain. Nefopam targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Mittur A. A Simultaneous Mixed-Effects Pharmacokinetic Model for Nefopam, N-desmethylnefopam, and Nefopam N-Oxide in Human Plasma and Urine. Eur J Drug Metab Pharmacokinet. 2018 Aug;43(4):391-404. [Content Brief]
- [2]. Kim KH, et al. Rediscovery of nefopam for the treatment of neuropathic pain. Korean J Pain. 2014 Apr;27(2):103-11. [Content Brief]
- [3]. Baht GS, et al. Pharmacologically targeting beta-catenin for NF1 associated deficiencies in fracture repair. Bone. 2017 May;98:31-36. [Content Brief]
